​

Atossa Therapeutics (ATOS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ATOS Stock Forecast

Atossa Therapeutics (ATOS) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $10.00, with a high of $10.00 and a low of $10.00. This represents a 325.53% increase from the last price of $2.35.

- $2 $4 $6 $8 $10 High: $10 Avg: $10 Low: $10 Last Closed Price: $2.35

ATOS Stock Rating

Atossa Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

ATOS Price Target Upside V Benchmarks

TypeNameUpside
StockAtossa Therapeutics325.53%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$10.00
Last Closing Price$2.35$2.35$2.35
Upside/Downside--325.53%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2612---3
May, 2612---3
Apr, 2613---4
Mar, 2613---4
Feb, 2613---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 12, 2026Craig-Hallum$10.00$3.84160.42%325.53%
Sep 08, 2023Louise ChenCantor Fitzgerald$5.00$0.83502.41%112.77%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 26, 2026H.C. WainwrightBuyBuyhold
Sep 11, 2024AscendiantBuyBuyhold
Jul 01, 2024H.C. WainwrightBuyBuyhold
May 13, 2024H.C. WainwrightBuyBuyhold
Sep 08, 2023Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.60$-3.00$-4.04---
Avg Forecast$-0.24$-0.22$-0.27$-0.31$0.21$0.52
High Forecast$-0.22$-0.21$-0.25$-0.29$0.68$0.52
Low Forecast$-0.25$-0.22$-0.29$-0.32$-0.27$0.52
Surprise %1400.00%1263.64%1396.30%---

Revenue Forecast

$50M $68M $86M $104M $122M $140M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$54.46M$82.35M$138.34M
High Forecast---$54.46M$82.35M$138.34M
Low Forecast---$54.46M$82.35M$138.34M
Surprise %------

Net Income Forecast

$-50M $-20M $10M $40M $70M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-30.09M$-25.50M$-34.77M---
Avg Forecast$-30.09M$-26.91M$-33.96M$-38.45M$8.02M$64.93M
High Forecast$-27.51M$-26.08M$-31.13M$-36.56M$85.74M$64.93M
Low Forecast$-31.63M$-27.32M$-36.11M$-40.35M$-34.04M$64.93M
Surprise %--5.23%2.37%---

ATOS Forecast FAQ

Is Atossa Therapeutics stock a buy?

Atossa Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Atossa Therapeutics is a favorable investment for most analysts.

What is Atossa Therapeutics's price target?

Atossa Therapeutics's price target, set by 5 Wall Street analysts, averages $10 over the next 12 months. The price target range spans from $10 at the low end to $10 at the high end, suggesting a potential 325.53% change from the previous closing price of $2.35.

How does Atossa Therapeutics stock forecast compare to its benchmarks?

Atossa Therapeutics's stock forecast shows a 325.53% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Atossa Therapeutics over the past three months?

  • June 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Atossa Therapeutics’s EPS forecast?

Atossa Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.31, marking a -92.33% decrease from the reported $-4.04 in 2025. Estimates for the following years are $0.21 in 2027, and $0.52 in 2028.

What is Atossa Therapeutics’s revenue forecast?

Atossa Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $54.46M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $82.35M, and $138.34M for 2028.

What is Atossa Therapeutics’s net income forecast?

Atossa Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-38.455M, representing an 10.60% increase from the reported $-34.77M in 2025. Projections indicate $8.02M in 2027, and $64.93M in 2028.